Mr. Bisaro has been a director and Board Chair since February 2024. He has more than 30 years of leadership at generic and pharmaceutical companies and a track record of driving growth through operational execution and corporate transformation.
Mr. Bisaro previously served as Chair of Mallinckrodt’s board from June 2022 to November 2023. He has also served as President, CEO and a director of Impax Laboratories, Executive Chairman of Amneal Pharmaceuticals, Executive Chairman of Allergan, President and CEO of Actavis (formerly Watson Pharmaceuticals), and President, Chief Operating Officer and a director of Barr Pharmaceuticals.
In addition to the Mallinckrodt board, Mr. Bisaro currently serves as a director on the boards of Myriad Genetics and Zoetis. He previously served on the boards of TherapeuticsMD and Zimmer Biomet.
Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a JD from The Catholic University of America.